Pharmacotherapy of social phobia

Acta Psychiatrica Scandinavica, Supplement

Volumn 108, Issue 417, 2003, Pages 65-71

  Davidson, Jonathan R T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Pharmacotherapy; Social phobia

Indexed keywords

ALPRAZOLAM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROFAROMINE; BUSPIRONE; CLONAZEPAM; FLUVOXAMINE; GABAERGIC RECEPTOR AFFECTING AGENT; GABAPENTIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; MONOAMINE OXIDASE A INHIBITOR; PREGABALIN;

CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; LONG TERM CARE; RELAPSE; SOCIAL PHOBIA; POPULATION RESEARCH; PRIORITY JOURNAL;

EID: 0141628578     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.108.s417.7.x     Document Type: Conference Paper

References (50)

1. VAN VLIET IM, DEN BOER JA, WESTENBERG HG. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994;115:128-134.
2. STEIN MB, FYER AJ, DAVIDSON JR et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999;156:756-760.
3. KATZELNICK DJ, KOBAK KA, GREIST JH et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-1371.
4. VAN AMERINGEN MA, LANE RM, WALKER JR et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001;158:275-281.
5. HAUG TT, HELLSTROM K, BLOMHOFF S et al. The treatment of social phobia in general practice. Is exposure therapy feasible? Fam Pract 2000;17:114-118.
6. BLOMHOFF S, HAUG TT, HOLME I et al. Randomized controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobia. Br J Psychiatry 2001;179:23-30.
7. STEIN MB, LIEBOWITZ MR, LYDIARD RB et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998;280:708-713.
8. ALLGULANDER C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 1999;100:193-198.
9. BALDWIN D, BOBES J, STEIN DJ et al. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 1999;175:120-126.
10. KELSEY JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995;31:767-771.
11. GELERNTER CS, UHDE TW, CIMBOLIC P et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991;48:938-945.
12. DAVIDSON JR, POTTS N, RICHICHI E et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423-428.
13. DAVIDSON JRT, TUPLER LA, POTTS NLS. Treatment of social phobia with benzodiazepines. J Clin Psychiatry 1994;55 (Suppl. 6):28-32.
14. VERSIANI M, NARDI AE, FIGUEIRA I et al. Double-blind placebo controlled trial with bromazepam in social phobia. J Bras Psiq 1997;46:167-171.
15. TUPLER LA, DAVIDSON JR, SMITH RD et al. A repeat proton magnetic resonance spectroscopy study in social phobia. Biol Psychiatry 1997;42:419-424.
16. PANDE AC, DAVIDSON JR, JEFFERSON JW et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-348.
17. PANDE AC, FELTNER DE, JEFFERSON JW et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled-multicenter study. J Clin Psychopharmacol in press.
18. LIEBOWITZ MR, SCHNEIER F, CAMPEAS R et al. Phenelzine vs. atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300.
19. HEIMBERG RG, LIEBOWITZ MR, HOPE DA et al. Cognitive behavioral group therapy vs. phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998;55:1133-1141.
20. VERSIANI M, NARDI AE, MUNDIM FD et al. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161:353-360.
21. NIEL JF, LICATA SM, MAY SJ et al. Dietary non-compliance during treatment with tranylcypromine. J Clin Psychiatry 1999;40:33-37.
22. NOYES R Jr, MOROZ G, DAVIDSON JR et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 1997;17:247-254.
23. SCHNEIER FR, GOETZ D, CAMPEAS R et al. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998;172:70-77.
24. International Multicenter Clinical Trial Group (IMCTG) on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neuorsci 1997;247:71-80.
25. LOTT M, GREIST JH, JEFFERSON JW et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 1997;17:255-260.
26. FAHLEN T, NILSSON HL, BORG K et al. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr Scand 1995;92:351-358.
27. VAN VLIET IM, DEN BOER JA, WESTENBERG HG. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992;2:21-29.
28. VAN VLIET IM, DEN BOER JA, WESTENBERG HG et al. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997;58:164-168.
29. 3 antagonist, ondansetron, in social phobia. Presented at the 33rd Annual Meeting of the American College of Neuropsychopharmacology, December 12-16. San Juan, Puerto Rico, 1994.
30. DAVIDSON JRT, MINER CM, DEVEAUGH-GEISS J et al. The Brief Social Phobia Scale: a psychometric evaluation. Psychol Med 1997;27:161-166.
31. TURNER SM, BEIDEL DC, COOLEY-QUILLE MR. Two-year follow-up of social phobias treated with Social Effectiveness Therapy. Behav Res Ther 1995;33:553-555.
32. SUTHERLAND SM, DAVIDSON JRT. Beta-blockers and benzodiazepines in pharmacotherapy. In: STEIN MB, ed. Social phobia - clinical and research perspectives. Washington, DC: American Psychiatric Press, Inc., 1995: 323-346.
33. VAN AMERINGEN M, MANCINI C, OAKMAN JM. Nefazodone in social phobia. J Clin Psychiatry 1999;60:96-100.
34. WORTHINGTON JJ III, ZUCKER BG, FONES CS et al. Nefazodone for social phobia: a clinical case series. Depress Anxiety 1998;8:131-133.
35. EMMANUEL NP, LYDIARD RB, BALLENGER JC. Treatment of social phobia with bupropion. J Clin Psychopharmacol 1991;11:276-277.
36. SIMPSON HB, SCHNEIER FR, MARSHALL RD et al. Low dose selegiline (L-Deprenyl) in social phobia. Depress Anxiety 1998;7:126-129.
37. HIDALGO RB, BARNETT SD, DAVIDSON JRT. Social anxiety disorder, two decades of progress. Int J Neurospychopharmacol 2001;4:279-298.
38. DAVIDSON JRT, HUGHES DL, GEORGE LK et al. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol Med 1993;23:709-718.
39. SUTHERLAND SM, TUPLER LA, COLKET JT et al. A 2-year follow-up of social phobia. Status after a brief medication trial. J Nerv Ment Dis 1996;184:731-738.
40. VERSIANI M, MUNDIAM FD, NARDI AE et al. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988;8:279-283.
41. SLAAP BR, VAN VLIET IM, WESTENBERG HG et al. Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response. J Affect Disord 1996;39:13-19.
42. CONNOR KM, DAVIDSON JR, POTTS NL et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 1998;18:373-378.
43. STEIN MB, CHARTIER MJ, HAZEN AL et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 1996;16:218-222.
44. COMPTON SN, GRANT PJ, CHRISMAN AK et al. Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry 2001;40:564-571.
45. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001;344:1279-1285.
46. GELENBERG AJ, LYDIARD RB, RUDOLPH RL et al. Efficacy of venlafaxine extended-release capsules in non-depressed outpatients with generalized anxiety disorder: a 6-month randomized clinical trial. JAMA 2001;61:356-360.
47. SCHNEIER FR, LIEBOWITZ MR, ABI-DARGHAM A et al. Low dopamine D (2) receptor binding potential in social phobia. Am J Psychiatry 2000;157:457-459.
48. TANCER ME. Neurobiology of social phobia. J Clin Psychiatry 1993;54 (Suppl.):26-30.
49. RANDALL CL, JOHNSON MR, THEROS A et al. Paroxetine improves social anxiety and alcohol use in dual-diagnosed patients: a pilot study. Depress Anxiety 2001;14:255-262.
50. FELTNER DE, POLLACK MH, Davidson JRT et al. A placebo-controlled, double-blind study of pregabalin treatment of social anxiety disorder: outcome and predictors of response. Poster presentation at 39th Meeting of the American College of European Neuropsychopharmacology, 2000, 5345.